Radiation therapy equipment developer RefleXion Medical and radiopharmaceutical company Telix Pharmaceuticals are investigating the clinical utility of combining their technologies for improving treatments for high-risk prostate and aggressive kidney cancers.
Under their strategic collaboration agreement, the firms will assess the potential of several new Telix PET tracers, including gallium-68 prostate-specific membrane antigen-11 for prostate cancer and Zr-89-girentuximab for kidney cancer, for guiding RefleXion's biology-guided radiotherapy technology.
